Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

PBH stands above SYK thanks to its solid earnings outlook, and based on these valuation figures, we also feel that PBH is the superior value option right now.

Gross margins declined to 66.4% in the first quarter from 67.6% a year ago due to increased depreciation, a higher mix of ...

Stryker (NYSE:SYK) announced today that it received FDA 510(k) clearance for its Incompass total ankle system.

This has positioned BSX as the second-largest player globally, largely due to the rapid adoption of pulsed field ablation ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our P/B Growth Investor model based on the published strategy of ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Penumbra's AI-guided aspiration system and scalable platform uniquely position it as a leader in stroke and PE intervention.